Kalciumfolinat Stada

Calcium folinate, the active ingredient in Kalciumfolinat Stada, is a folate analog presented as a sterile injectable solution for intramuscular or intravenous use. It is employed to rescue normal cells from the toxic effects of antifolate chemotherapy and to correct folate deficiency in patients receiving such treatment.

GNH USA supplies Kalciumfolinat Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Kalciumfolinat Stada provides reduced‑form folate to support patients in clinical situations where folate pathways are compromised. - Methotrexate toxicity rescue: restores folate‑dependent processes and reduces adverse effects of high‑dose methotrexate. - Folate deficiency: replenishes systemic folate stores in patients with inadequate dietary intake or malabsorption. - Adjunct in chemotherapy regimens: enhances tolerability of antifolate‑based protocols by protecting normal tissues.

Adverse reactions may occur with calcium folinate administration.

Common Side Effects: - Nausea or vomiting - Transient headache - Mild injection site erythema - Low‑grade fever - Diarrhea - Elevated liver enzymes

Serious or Rare Side Effects: - Severe hypersensitivity or anaphylaxis - Acute renal impairment - Significant neutropenia or thrombocytopenia - Pulmonary toxicity (interstitial pneumonitis) - Cardiac arrhythmias in patients with electrolyte disturbances - Unexplained bleeding or coagulopathy

When using calcium folinate, clinicians should observe several safety measures. - Renal function monitoring: adjust dosing in patients with impaired clearance. - Hepatic function monitoring: watch for elevated transaminases. - Hypersensitivity assessment: discontinue if severe allergic reaction occurs. - Concomitant high‑dose folate antagonists: avoid or adjust therapy. - Pregnancy and lactation: evaluate risk‑benefit before use. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Calcium folinate can interact with several medicines; awareness of the interaction level is essential.

Major Interactions (Avoid): - High‑dose methotrexate: may reduce rescue efficacy. - Trimethoprim‑sulfamethoxazole: competitive folate antagonism. - Phenytoin: may alter folate metabolism.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may affect renal clearance. - Penicillins (e.g., ampicillin): potential additive hematologic effects. - Anticonvulsants (e.g., carbamazepine): may increase folate requirement.